Prognostic Score of Palmer et al for a Patient with Advanced Renal Cell Carcinoma Treated with Recombinant Interleukin-2

Description

Palmer et al identified prognostic factors for patients with advanced (metastatic) renal cell carcinoma who are treated with recombinant interleukin-2. The factors are known at the time of enrollment into the study and can be used to stratify patients based on risk. The authors are from EuroCetus BV in Amsterdam, Centre Leon Berard in Lyon and MHH University Medical School in Hannover.

Selection criteria:

(1) metastatic renal cell carcinoma

(2) ECOG performance status 0 or 1 (ambulatory)

(3) no CNS metastases

(4) serum bilirubin, serum creatinine and hemoglobin within the normal range

(5) no major organ compromise

(6) measurable disease

Parameters:

(1) ECOG performance scale

(2) number of metastastic sites (lung, bone and/or "other")

(3) time from initial diagnosis to enrollment for therapy

Parameter	Finding	Points
ECOG performance scale	0	0
	1	1
number of metastatic sites	1	0
	2 or 3	1
time from initial diagnosis	<= 24 months	1
	> 24 months	0

total number of risk factors =

= SUM(points for all 3 parameters)

Interpretation:

• minimum number of risk factors: 0

• maximum number of risk factors: 3

Risk Score	Risk Group	Median Survival
0	very low	28 months
1	low	17 months
2	medium	10 months
3	high	5 months

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10